Cardax

Cardax EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Cardax (CDXI) as of Oct 20, 2026 is -2.66. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -0.73 — a change of 265.09% (lower).

EV/FCF

-2.66

YoY

265.09%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Cardax is 2020 -2.66 . EV/FCF (Enterprise Value to Free Cash Flow) of Cardax was 2019 -0.73 . It decreases by 265.09% lower compared to the previous year.

The Cardax EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2015
0.21 USD
Jan 1, 2016
0.13 USD
Jan 1, 2017
1.08 USD
Jan 1, 2018
0.08 USD
Jan 1, 2019
-0.73 USD
Jan 1, 2020
-2.66 USD
The Cardax EV/FCF history
YEAREV/FCFYoY
-2.66+265.09%
-0.73-1,056.10%
0.08-92.91%
1.08+753.01%
0.13-41.30%
0.21—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardax Stock analysis

What does Cardax do? Cardax Inc, a development stage biopharmaceutical company based in Honolulu, Hawaii, focuses on developing pharmaceuticals for chronic diseases driven by inflammation. The company has 10 full-time employees and went public via an IPO on January 30, 2012. Cardax is currently developing two pre-clinical pharmaceutical candidates: CDX-101 and CDX-301. CDX-101 is a proprietary astaxanthin prodrug designed to deliver astaxanthin to the bloodstream following oral administration. Astaxanthin is a naturally occurring molecule known for its anti-inflammatory properties, supporting cardiovascular health, metabolic health, liver health, joint health, and longevity. CDX-301 is a pharmaceutical candidate for macular degeneration, utilizing zeaxanthin, which accumulates in the human eye through a retinal receptor to protect against blue light, oxidative damage, and inflammation associated with macular degeneration. The company's headquarters are located in Honolulu, and it operates within the Health Care sector, specifically in the Pharmaceuticals industry. Cardax Inc's website is https://cardaxpharma.com/. The company is seeking to monetize its pre-clinical candidates, CDX-101 and CDX-301, as it advances its development pipeline. No additional details about the company's financials, specific acquisition history, or other product names are provided in the available information. Cardax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cardax stock

EV/FCF (Enterprise Value to Free Cash Flow) of Cardax is -2.66 in 2020.

EV/FCF (Enterprise Value to Free Cash Flow) of Cardax changed from -0.73 to -2.66, representing a 265.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Cardax since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Cardax with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cardax

All Key Metrics — Cardax